Breakdown | ||||
Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
39.14B | 39.10B | 38.98B | 36.78B | 36.50B | Gross Profit |
12.62B | 12.49B | 15.74B | 15.42B | 15.33B | EBIT |
3.46B | 4.17B | 6.63B | 6.13B | 5.63B | EBITDA |
8.75B | 10.71B | 10.25B | 10.25B | 10.18B | Net Income Common Stockholders |
1.52B | 2.80B | 4.32B | 4.37B | 4.96B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
22.00B | 19.42B | 18.86B | 14.36B | 20.55B | Total Assets |
97.89B | 100.04B | 102.18B | 98.97B | 105.64B | Total Debt |
13.67B | 5.82B | 8.89B | 10.00B | 330.00M | Net Debt |
-8.34B | -13.60B | -9.97B | -4.36B | -20.22B | Total Liabilities |
23.56B | 13.92B | 18.50B | 18.97B | 9.69B | Stockholders Equity |
74.32B | 86.11B | 83.61B | 79.96B | 95.88B |
Cash Flow | Free Cash Flow | |||
6.53B | 4.32B | 7.78B | 5.30B | -686.00M | Operating Cash Flow |
11.76B | 7.12B | 9.18B | 8.50B | 6.85B | Investing Cash Flow |
-4.12B | -3.26B | -1.95B | -3.81B | -6.95B | Financing Cash Flow |
-5.46B | -3.89B | -3.14B | -11.05B | -2.50B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | ¥55.17B | 57.54 | 1.87% | 1.94% | 0.10% | -41.21% | |
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
€981.87M | 28.57 | 4.78% | 2.74% | ― | ― | ||
$966.58M | 17.10 | 6.55% | 3.60% | ― | ― | ||
76 Outperform | ¥118.12B | 19.57 | 3.25% | 11.54% | -8.30% | ||
72 Outperform | ¥21.64B | 16.03 | 2.16% | 14.12% | 56.92% | ||
53 Neutral | ¥10.31B | 116.15 | 4.03% | 6.83% | ― |
Hogy Medical Co., Ltd.’s Board of Directors has decided to oppose a shareholder proposal from Nippon Active Value Fund plc regarding the election of three directors at the upcoming Annual General Meeting. The Board believes that its current composition, which includes a Nomination Committee to ensure independence and accountability, is optimal for implementing its medium-term management plan aimed at sustainable growth and enhanced corporate governance.
The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.
Hogy Medical Co., Ltd. announced a significant change in its leadership structure, with Taisuke Fujita being appointed as the new Representative Director and Vice President, effective June 20, 2025. This strategic move aims to strengthen the company’s management framework, potentially impacting its operational efficiency and market positioning. Additionally, the company will see the resignation of two outside directors, Kiyoshi Uesugi and Yuta Kinose, on the same date.
The most recent analyst rating on (JP:3593) stock is a Hold with a Yen3700.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.
Hogy Medical Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a slight increase in net sales by 0.1% to ¥39,138 million. However, the company experienced a significant decline in profits, with operating profit down by 8.6% and profit attributable to owners of the parent down by 45.8%. Despite these challenges, the company maintained its dividend payments and forecasts a recovery in profits for the next fiscal year, indicating a strategic focus on improving financial performance.